Therefore, combination therapy utilising AEP‐targeted inhibitors and CD74/MIF pathway inhibitors may provide comprehensive inhibition of distant organ metastasis in breast cancer, potentially emerging as a promising clinical strategy for future therapeutic development. The gene discussed is MIF; the disease is breast carcinoma.